SCYNEXIS, Inc. (SCYX) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of SCYNEXIS, Inc. (NASDAQ:SCYX) from a hold rating to a buy rating in a report issued on Tuesday. Zacks Investment Research currently has $2.00 price target on the stock.
According to Zacks, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. “
A number of other brokerages have also weighed in on SCYX. Aegis restated a buy rating on shares of SCYNEXIS in a report on Tuesday, May 30th. Needham & Company LLC lowered shares of SCYNEXIS from a buy rating to a hold rating in a report on Tuesday, May 9th. Roth Capital set a $9.00 price objective on shares of SCYNEXIS and gave the stock a buy rating in a report on Monday, August 7th. HC Wainwright set a $14.00 price objective on shares of SCYNEXIS and gave the stock a buy rating in a report on Wednesday, August 16th. Finally, ValuEngine lowered shares of SCYNEXIS from a sell rating to a strong sell rating in a report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $10.22.
Shares of SCYNEXIS (NASDAQ SCYX) opened at 1.92 on Tuesday. The stock’s market capitalization is $51.31 million. The company’s 50 day moving average price is $1.75 and its 200-day moving average price is $2.21. SCYNEXIS has a 12 month low of $1.52 and a 12 month high of $5.51.
ILLEGAL ACTIVITY WARNING: “SCYNEXIS, Inc. (SCYX) Upgraded at Zacks Investment Research” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/01/scynexis-inc-scyx-upgraded-at-zacks-investment-research.html.
In related news, Director David C. Hastings bought 20,000 shares of the firm’s stock in a transaction on Wednesday, June 21st. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $35,000.00. Following the purchase, the director now owns 20,000 shares in the company, valued at $35,000. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders have acquired 45,000 shares of company stock valued at $75,850. Company insiders own 3.91% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Iguana Healthcare Management LLC raised its stake in shares of SCYNEXIS by 20.0% in the first quarter. Iguana Healthcare Management LLC now owns 300,000 shares of the company’s stock worth $828,000 after buying an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of SCYNEXIS by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock worth $103,000 after buying an additional 512 shares in the last quarter. KCG Holdings Inc. bought a new stake in shares of SCYNEXIS during the first quarter worth $416,000. Private Advisor Group LLC bought a new stake in shares of SCYNEXIS during the first quarter worth $555,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of SCYNEXIS during the first quarter worth $154,000. Institutional investors and hedge funds own 36.75% of the company’s stock.
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related stocks with our FREE daily email newsletter.